GENETICS OF SYSTEMIC LUPUS ERYTHEMATOSUS: Clinical Implications
Section snippets
Single Gene Effects
The traditional goal of genetic analysis is to identify the single gene implicated in the disease under study. It is anticipated that after the identification of the gene, the disease would either become a candidate for gene therapy or identification of the gene would lead to specific therapy directed at the defective biochemical pathway. Although gene therapy has been shown to be effective in the rare adenosine deaminase deficiency,10, 13 this type of intervention has yet to fulfill its
Association Studies
There are two main methods to identify genetic susceptibility factors in polygenic disorders: association studies and linkage analysis. Association studies examine the frequency of a mutation or polymorphism in the affected population and compare the frequency to that seen in a matched control population. In the past, restriction fragment length polymorphisms were often used, but most laboratories now use polymerase chain reaction–based techniques to identify the specific mutation,
CURRENT UNDERSTANDING OF THE GENETICS OF SYSTEMIC LUPUS ERYTHEMATOSUS
The pathophysiology is better established for SLE than for any other autoimmune disease with the possible exception of ankylosing spondylitis. The genetic factors identified in SLE to date include genes known to affect immune complex clearance, genes implicated in tolerance, MHC genes, and genes regulating inflammation. This section reviews our current understanding of the genetic contributions to the development of SLE.
Human Studies
The current strategies for the treatment of SLE have not changed dramatically over the past 20 years, although they have been significantly refined, and the mortality and morbidity statistics suggest overall improvement.168 Nevertheless, the dominant strategy remains global immunosuppression with glucocorticoids or antiproliferative agents such as cyclophosphamide. Many new clinical trials are exploring variations on this theme to optimize the antiautoimmunity effect and minimize the
FUTURE OPTIONS
The main direct benefit of genetic analysis of SLE is a greater understanding of its etiopathogenesis. This has already led to the development and testing of new strategies directed at immune complex clearance, tolerance, apoptosis, and cytokine regulation. It is hoped that these new biologic strategies have a more specific effect on the disease process compared with global immunosuppression.
References (190)
- et al.
Recent trends in glutathione biochemistry–glutathione-protein interactions: A molecular link between oxidative stress and cell proliferation
Biochem Biophys Res Commun
(1998) - et al.
Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
Cell
(1995) - et al.
Reactive oxygen species. Modified polyguanylate acid: Immunogenicity and implications for systemic autoimmunity
J Autoimmun
(1998) - et al.
The genetics of human systemic lupus erythematosus
Curr Opin Immunol
(1998) - et al.
Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus-probe mice (gld) by Fas-ligand gene transfer
J Autoimmun
(1998) - et al.
Systemic lupus erythematosus with nephritis is strongly associated with the TNFB*2 homozygote in the Korean population
Hum Immunol
(1996) - et al.
FcgRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cells FcgRIIIa, independently of the FcgRIIIa-48L/R/H phenotype
Blood
(1997) - et al.
Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: Role of decreased intracellular TNFa
Clin Immunol Immunopathol
(1996) - et al.
The -308 tumor necrosis factor–a promoter polymorphism effects transcription
Mol Immunol
(1997) - et al.
Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes
Cytokine
(1998)
Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha
Clin Exp Immunol
Differential oncogene and TNFa mRNA expression in bone marrow cells from systemic lupus erythematosus patients
Arthritis Rheum
Bromocriptine in systemic lupus erythematosus: A double blind, randomized placebo controlled study
Arthritis Rheum
C2 deficiency in blood donors and lupus patients: Prevalence, clinical characteristics and HLA-associations in the Brazilian population
Lupus
High levels of Bcl-2 protein in circulating T lymphocytes, but not B lymphocytes of patients with systemic lupus erythematosus
Arthritis Rheum
Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide
Clin Exp Rheumatol
In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: Lack of relationship with clinical disease activity
Lupus
Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus
Clin Exp Immunol
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune disease
Proc Natl Acad Sci USA
T-lymphocyte directed gene therapy for ADA-SCID: Initial trial results after 4 years
Science
Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus
Arthritis Rheum
Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of twelve additional sets
Am J Med
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients
Science
Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): No association with disease
Clin Exp Immunol
FcRIIa polymorphism in systemic lupus erythematosus (SLE): No association with disease
Clin Exp Immunol
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptic bodies
Nat Gene
Secretion of tumour necrosis factor a and lymphotoxin a in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease
Scand J Immunol
Hereditary C1q deficiency and systemic lupus erythematosus
QJM
Tumor necrosis factor and IL-1 in New Zealand black/white mice
J Immunol
Relevance of the tumor necrosis factor alpha (TNFa)-308 promoter polymorphism in TNFa gene regulation
J Inflamm
Ballerini C, Audino S, et al: Fas gene polymorphisms are not associated with systemic lupus erythematosus, multiple sclerosis and HIV infection
Dis Markers
A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL/1pr mice
J Immunol
Estradiol enhances leukocyte binding to tumor necrosis factor stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type I, and vascular adhesion molecule type I
J Clin Invest
An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus
J Clin Invest
Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide
Science
The delta 32 deletion of CCR5 receptor in rheumatoid arthritis
Arthritis Rheum
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; Reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis
J Clin Invest
Lymphotoxin α3 induces chemokines and adhesion molecules: Insight into the role of LTa in inflammation and lymphoid organ development
J Immunol
T-cell-dependent immune responses in C1q-deficient mice: Defective interferon gamma production by antigen specific T cells
J Exp Med
Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population
Tissue Antigens
The immune response to anti-B7 antibodies is dose dependent: Low doses elicit a potent response while high doses block the immune response
Arthritis Rheum
Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism
Clin Exp Immunol
Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus
Dis Markers
A dysfunctional allele of the mannose binding protein gene associates with systemic lupus erythematosus in a Spanish population
J Rheumatol
Mannose binding protein gene polymorphism in systemic lupus erythematosus
Arthritis Rheum
Relative contributions of HLA-DQA and complement C4A loci in determining susceptibility to systemic lupus erythematosus
Br J Rheumatol
Splenic uptake of immune complexes in man is complement dependent
J Immunol
A revised estimate of twin concordance in systemic lupus erythematosus
Arthritis Rheum
Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production
J Clin Invest
Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus in southern Chinese
Arthritis Rheum
Cited by (74)
Systemic lupus erythematosus (I)
2021, Medicine (Spain)Discoid Lupus Erythematosus
2018, AlopeciaApplication of nanoparticle technology in the treatment of Systemic lupus erythematous
2016, Biomedicine and PharmacotherapySystemic Lupus Erythematosus
2016, Encyclopedia of ImmunobiologyThe immunopathology of cutaneous lupus erythematosus
2014, Rheumatic Disease Clinics of North AmericaAdvances in systemic lupus erythematosus
2014, Medicine (United Kingdom)Citation Excerpt :There is an interaction between gene susceptibility, hormonal influences and some environmental triggers, which induce antibody production and the consequent inflammatory response leading to the induction and maintenance of the disease. The genetic component in SLE pathogenesis was first suggested by the evident concordance between monozygotic twins in 24–69% compared to 1–5% in dizygotic twins,4,5 and also by the different prevalence in various ethnic groups. Some rare genetic mutations associated with familial SLE-like disease, transmitted in a Mendelian fashion, have been identified but these account for only 1–2% of cases.
Address reprint requests to Kathleen E. Sullivan, MD, PhD, Division of Immunologic and Infectious Diseases, Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104
- *
Division of Immunologic and Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania